A Phase 3 interventional study of Diacerein and Celecoxib in Osteoarthritis and Osteoarthritis, Knee, sponsored by TRB Chemedica International SA. Completed at 22 sites in 5 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by TRB Chemedica International SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 41 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 16th largest by enrollment of the 160 interventional ones that give a count, is one of 6 that started in 2016, is one of 20 in phase 3, and was the 73rd registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 7 more countries
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 40–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 25 · Phase 4 10
First in 1999; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 65 across the 160 interventional studies, 48 across the 10 observational. Of the 105 that completed or were terminated, 29 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 171 have an industry lead sponsor. The 10 most frequent:
TRB Chemedica International SA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
TRB Chemedica International SA has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoarthritis, Knee with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283889University of CalgaryGenicular Radiofrequency Ablation Following Total Knee Arthroplasty | 2026-12 |
| NCT04378049McMaster UniversityRobot-Assisted Partial Knee Replacement Versus Standard Total Knee Replacement | 2026-12 |
| NCT01674816Centre hospitalier de l'Université de Montréal (CHUM)Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration | 2026-12-01 |
| NCT06166628David ClinkardGenicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis | 2026-12-01 |
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteoarthritis (OA) of the knee is the most frequent cause of knee pain after the age of 50 years. OA is a joint disease characterised by articular cartilage loss associated with structural changes in the cartilage and adjacent structures. The main symptoms are pain and functional disability. The goals of OA therapy are to decrease pain and maintain or improve joint function. There is evidence that diacerein has both a symptomatic and a structural effect on cartilage, and clinical studies suggest that diacerein therapy significantly decreases OA symptoms when compared to placebo. Diacerein has been shown to inhibit interleukine-1 (IL-1β), and down-regulated IL-1β stimulated secretion of metalloproteinases and aggrecanases, and thereby prevent breakdown of cartilage by these enzymes. Diacerein has no effect on the synthesis of prostaglandins, and therefore no effect on the upper intestinal tract. The purpose of this phase III-IV international, multicentre, double-blind, non-inferiority, randomised, controlled study is to determine the efficacy and safety of diacerein vs. celecoxib on symptoms after 6 months of treatment, and on structural changes after 2 years of treatment in knee OA patients as assessed by magnetic resonance imaging (MRI).
The study was a phase III (Canada and Belgium) or IV (Spain, Austria and Czech Republic) international, multicentre, double-blind, randomized, controlled, parallel-groups, symptom-modifying and structure-modifying clinical study of Diacerein (50 mg twice daily) versus Celecoxib (200 mg once daily).
It was planned that 400 patients (males and females) of at least 50 years of age would take part in the study (approximately 150 patients in Canada and 250 patients in European countries). All patients were included after a Screening Visit (washout of previous medication for osteoarthritis) and randomized at the Inclusion Visit (Day 0) in 2 treatment groups of 200 patients as follows:
The duration of the double-blind study for each patient was up to 182 ± 7 days for the symptom study.
During the study, patients were allowed to take acetaminophen 500 mg, to a maximum of 2 g per day, dispensed at each visit by the investigator for rescue therapy.
Pain and other functional symptoms were primary analysed after 6 months (182 days) of treatment (symptom study).
Acetaminophen was dispensed during the study as rescue therapy in case of pain. However, it was asked to discontinue acetaminophen 48 hours before each study procedure/assessment of efficacy.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
This study's enrollment of 380 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →TRB Chemedica International SA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria related to individual characteristics of the patient
Treatment-Related Exclusion:
Criteria-Related to Magnetic Resonance Imaging (MRI):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
Drug: Diacerein · Drug: Placebo
One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
Drug: Celecoxib · Drug: Placebo
Change Form Baseline in WOMAC A Pain Subscale
Change form baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) A pain subscale after 182 days of treatment. WOMAC A pain subscale: 0 - 50 cm; 50 = worse
Time frame: baseline and 182 days
Change From Baseline in WOMAC OA Scores
Absolute Changes from Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) after 182 days of treatment. WOMAC scale: 0 - 240 cm; 240 = worse - Intention-To-Treat (N=370) Pain subscale: 0-50cm; 50 = worse; Stifness subscale: 0-20cm; 20 = worse; Function subscale: 0-170cm; 170 = worse Absolute changes in WOMAC scores: \<0 = improvement; 0 = stable; \>0 = worsening
Time frame: Day 182 or early termination
Absolute Changes From Baseline in Pain Visual Analogue Scale
Absolute Changes from Baseline in Pain Visual Analogue Scale (VAS): 0-10 cm; 10 = worse
Time frame: Day 182 or early termination
OARSI Responders
Osteoarthritis Research Society International (OARSI) Responders
Time frame: Day 182 or early termination
Assessment of Joint Swelling, Effusion or Both
Assessment of Joint Swelling, joint Effusion or Both
Time frame: Day 182 or early termination
Consumption of Acetaminophen
Overall Daily number of tablets taken during the 6 month study
Time frame: Day 182 or early termination
Change From Baseline in Patient's Global Assessment of Disease Activity
Change from baseline in global assessment of disease activity was assessed using a VAS scale (0-10cm; 10=worse)
Time frame: Day 182 or early termination
Global Assessment of Response to Therapy
Between group comparison in Patient's and Investigator's Global Assessment of Response to Therapy using a 0-10 cm disease activity VAS scale: 0 cm = very well; 10 cm = very poorly
Time frame: Day 182 or early termination
Quality of Life SF-36
Absolute Changes from Baseline in Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the Quality of Life questionnaire SF-36. Scale range for each component (PCS and MCS): minimum = 0, maximum = 100, with higher scores indicating better quality of life. Absolute changes in each component (PCS and MCS): \>0 = improvement; 0 = stable; \<0 = worsening.
Time frame: Day 182 or early termination
Cartilage Volume Loss From Baseline in the Medial Compartment Using MRI
Relative cartilage volume loss from baseline in the medial compartment of the knee using MRI
Time frame: baseline and 728 days
Cartilage Volume Loss From Baseline in the Lateral Compartment Using MRI
Relative cartilage volume loss from baseline in the lateral compartment of the knne using MRI
Time frame: baseline and 728 days
Change From Baseline in Synovitis (Synovial Membrane Thickness) Using MRI
Absolute Change from baseline in synovitis (synovial membrane thickness) in the global knee using MRI
Time frame: baseline and 728 days
Change From Baseline in WOMAC A Pain Subscale
Relative mean change from baseline in WOMAC Pain subscore
Time frame: baseline and 728 days
Change From Baseline in Global Stiffness Using WOMAC Subscale
Relative Change from baseline in global stiffness using WOMAC subscale
Time frame: baseline and 728 days
Change From Baseline in Visual Analogue Scale Pain (VAS-Huskisson's)
Relative change from baseline in Visual Analogue Scale pain (VAS-Huskisson's)
Time frame: baseline and 728 days
| Milestone | Diacerein | Celecoxib |
|---|---|---|
| Started | 187 | 193 |
| Completed | 141 | 149 |
| Not completed | 46 | 44 |
| Withdrew: Protocol violation | 2 | 5 |
| Withdrew: Lack of efficacy | 7 | 7 |
| Withdrew: Adverse event | 21 | 12 |
| Withdrew: Withdrawal by subject | 15 | 13 |
| Withdrew: No study medication intake | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 3 |
Change form baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) A pain subscale after 182 days of treatment. WOMAC A pain subscale: 0 - 50 cm; 50 = worse
| cm | Diacerein | Celecoxib |
|---|---|---|
| Change Form Baseline in WOMAC A Pain Subscale | -11.14 ± 0.91 | -11.82 ± 0.89 |
Absolute Changes from Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) after 182 days of treatment. WOMAC scale: 0 - 240 cm; 240 = worse - Intention-To-Treat (N=370) Pain subscale: 0-50cm; 50 = worse; Stifness subscale: 0-20cm; 20 = worse; Function subscale: 0-170cm; 170 = worse Absolute changes in WOMAC scores: \<0 = improvement; 0 = stable; \>0 = worsening
| score | Diacerein | Celecoxib |
|---|---|---|
| Total Score | -41.0 ± 53.1 | -42.9 ± 55.0 |
| Pain Score | -10.03 ± 11.95 | -9.60 ± 12.02 |
| Stiffness Score | -3.56 ± 4.99 | -3.99 ± 5.32 |
| Physical Function Score | -27.2 ± 39.0 | -29.3 ± 39.8 |
Absolute Changes from Baseline in Pain Visual Analogue Scale (VAS): 0-10 cm; 10 = worse
| score | Diacerein | Celecoxib |
|---|---|---|
| Absolute Changes From Baseline in Pain Visual Analogue Scale | -2.34 ± 2.55 | -2.46 ± 2.61 |
Osteoarthritis Research Society International (OARSI) Responders
| Participants | Diacerein | Celecoxib |
|---|---|---|
| OARSI Responders | 99 | 97 |
Assessment of Joint Swelling, joint Effusion or Both
| participants | Diacerein | Celecoxib |
|---|---|---|
| Joint Swelling | 47 | 48 |
| Joint Effusion | 37 | 37 |
| Joint Swelling and Effusion | 19 | 23 |
Overall Daily number of tablets taken during the 6 month study
| tablets | Diacerein | Celecoxib |
|---|---|---|
| Consumption of Acetaminophen | 1.06 ± 1.75 | 0.91 ± 1.02 |
Change from baseline in global assessment of disease activity was assessed using a VAS scale (0-10cm; 10=worse)
| score | Diacerein | Celecoxib |
|---|---|---|
| Patient's Global Assessment | -1.81 ± 2.79 | -1.97 ± 2.97 |
| Investigator's Global Assessment | -2.02 ± 2.55 | -2.65 ± 2.55 |
Between group comparison in Patient's and Investigator's Global Assessment of Response to Therapy using a 0-10 cm disease activity VAS scale: 0 cm = very well; 10 cm = very poorly
| score on a scale | Diacerein | Celecoxib |
|---|---|---|
| Patient's Global Assessement | 3.89 ± 2.57 | 3.61 ± 2.52 |
| Investigator's Global Assessment | 3.85 ± 2.51 | 3.35 ± 2.42 |
Absolute Changes from Baseline in Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the Quality of Life questionnaire SF-36. Scale range for each component (PCS and MCS): minimum = 0, maximum = 100, with higher scores indicating better quality of life. Absolute changes in each component (PCS and MCS): \>0 = improvement; 0 = stable; \<0 = worsening.
| score on a scale | Diacerein | Celecoxib |
|---|---|---|
| Physical Component Summary | 2.46 ± 6.74 | 4.57 ± 8.08 |
| Mental Component Summary | 1.56 ± 8.34 | -0.14 ± 8.87 |
Relative cartilage volume loss from baseline in the medial compartment of the knee using MRI
| percentage of volume loss | Diacerein | Celecoxib |
|---|---|---|
| Cartilage Volume Loss From Baseline in the Medial Compartment Using MRI | -4.8 ± 6.3 | -6.0 ± 6.7 |
Relative cartilage volume loss from baseline in the lateral compartment of the knne using MRI
| percentage of volume loss | Diacerein | Celecoxib |
|---|---|---|
| Cartilage Volume Loss From Baseline in the Lateral Compartment Using MRI | -4.4 ± 4.4 | -4.1 ± 4.0 |
Absolute Change from baseline in synovitis (synovial membrane thickness) in the global knee using MRI
| mm | Diacerein | Celecoxib |
|---|---|---|
| Change From Baseline in Synovitis (Synovial Membrane Thickness) Using MRI | 0.24 ± 0.18 | 0.27 ± 0.15 |
Relative mean change from baseline in WOMAC Pain subscore
| percentage of change in WOMAC Pain score | Diacerein | Celecoxib |
|---|---|---|
| Change From Baseline in WOMAC A Pain Subscale | -26.2 ± 48.0 | -37.1 ± 52.2 |
Relative Change from baseline in global stiffness using WOMAC subscale
| percentage of change in WOMACStifness sc | Diacerein | Celecoxib |
|---|---|---|
| Change From Baseline in Global Stiffness Using WOMAC Subscale | -24.3 ± 46.6 | -38.1 ± 44.5 |
Relative change from baseline in Visual Analogue Scale pain (VAS-Huskisson's)
| Percentage of change in VAS score | Diacerein | Celecoxib |
|---|---|---|
| Change From Baseline in Visual Analogue Scale Pain (VAS-Huskisson's) | -31.4 ± 43.8 | -37.6 ± 44.4 |
Collected over At each post-screening visit up to 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diacerein | 0/186 (0%) | 3/186 (1.6%) | 49/186 (26.3%) |
| Celecoxib | 0/190 (0%) | 4/190 (2.1%) | 33/190 (17.4%) |
| Event | Diacerein | Celecoxib |
|---|---|---|
| Gamma-glutamyltransferase increasedInvestigations | 1/186 | 0/190 |
| Transaminases increasedInvestigations | 1/186 | 0/190 |
| Neoplasm prostateNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/186 | 0/190 |
| Abdominal painGastrointestinal disorders | 1/186 | 0/190 |
| DepressionPsychiatric disorders | 1/186 | 0/190 |
| Temporal arteritisVascular disorders | 0/186 | 1/190 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/186 | 1/190 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/186 | 1/190 |
| Cerebrovascular accidentNervous system disorders | 0/186 | 1/190 |
| Event | Diacerein | Celecoxib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/186 | 7/190 |
| Abdominal painGastrointestinal disorders | 6/186 | 2/190 |
| Faeces softGastrointestinal disorders | 3/186 | 6/190 |
| ChromaturiaGastrointestinal disorders | 5/186 | 0/190 |
| DyspepsiaGastrointestinal disorders | 5/186 | 5/190 |
| Abdominal pain upperGastrointestinal disorders | 4/186 | 1/190 |
| HeadacheNervous system disorders | 1/186 | 3/190 |
| ConstipationGastrointestinal disorders | 2/186 | 0/190 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/186 | 0/190 |
| HaematuriaGastrointestinal disorders | 2/186 | 0/190 |
All randomized patients
| Age, Categorical(Participants) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 106 | 97 | 203 |
| >=65 years | 81 | 96 | 177 |
| Age, Continuous(years) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| Mean | 63.7 ± 6.3 | 64.4 ± 7.0 | 64.1 ± 6.7 |
| Sex: Female, Male(Participants) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| Female | 137 | 146 | 283 |
| Male | 50 | 47 | 97 |
| Race and Ethnicity Not Collected(Participants) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| Canada | 80 | 79 | 159 |
| Austria | 3 | 6 | 9 |
| Belgium | 2 | 1 | 3 |
| Czechia | 59 | 63 | 122 |
| Spain | 43 | 44 | 87 |
| Study Knee(participants) | Diacerein | Celecoxib | Total |
|---|---|---|---|
| Right knee | 87 | 96 | 183 |
| Left knee | 100 | 97 | 197 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Jun 2018, 25 months.
Results were first posted in Dec 2023, 5 years 5 months after primary completion.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 25 months is above that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diacerein
TRB Chemedica International SA